Sei Investments Co. Takes Position in SOPHiA GENETICS SA $SOPH

Sei Investments Co. purchased a new stake in shares of SOPHiA GENETICS SA (NASDAQ:SOPH) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 357,888 shares of the company’s stock, valued at approximately $1,772,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Silverberg Bernstein Capital Management LLC lifted its holdings in SOPHiA GENETICS by 8.7% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock worth $257,000 after buying an additional 4,155 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of SOPHiA GENETICS by 24.7% in the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after acquiring an additional 6,205 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares during the last quarter. First Dallas Securities Inc. purchased a new position in SOPHiA GENETICS in the first quarter valued at about $50,000. Finally, Squarepoint Ops LLC acquired a new stake in SOPHiA GENETICS during the 3rd quarter valued at approximately $49,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Wall Street Analysts Forecast Growth

SOPH has been the topic of several analyst reports. HC Wainwright lifted their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. BTIG Research lifted their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.00.

Insider Buying and Selling

In other SOPHiA GENETICS news, CEO Ross Muken sold 9,838 shares of SOPHiA GENETICS stock in a transaction on Monday, July 6th. The shares were sold at an average price of $5.22, for a total value of $51,354.36. Following the completion of the transaction, the chief executive officer owned 670,651 shares of the company’s stock, valued at $3,500,798.22. The trade was a 1.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jurgi Camblong sold 50,069 shares of the business’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $5.80, for a total transaction of $290,400.20. Following the sale, the chief executive officer owned 3,601,493 shares of the company’s stock, valued at approximately $20,888,659.40. The trade was a 1.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 276,092 shares of company stock worth $1,637,350 over the last ninety days. 4.88% of the stock is owned by insiders.

SOPHiA GENETICS News Roundup

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: BTIG Research raised its price target for SOPH from $8 to $9 while maintaining a Buy rating. The move adds to recent analyst support and reinforces the stock’s upward momentum. BTIG Research raises SOPHiA GENETICS price target
• Positive Sentiment: SOPHiA GENETICS reached a new 12-month high following the analyst upgrade, indicating strong investor demand and a favorable near-term trading reaction. SOPHiA GENETICS reaches a new 12-month high
• Positive Sentiment: HC Wainwright continues to rate SOPH Buy with a $14 price target, well above recent trading levels. Its longer-term forecast still calls for a return to profitability, including positive EPS estimates for 2029 and 2030.
• Neutral Sentiment: Chief Technology Officer Abhimanyu Verma sold 5,000 shares for approximately $34,750 under a pre-arranged Rule 10b5-1 plan. Because the sale was scheduled in advance and reduced his ownership by only 2.6%, it carries limited signaling value.
• Negative Sentiment: HC Wainwright lowered EPS estimates across several periods: Q3 2026 to $(0.13), FY2026 to $(0.77) from $(0.58), FY2027 to $(0.31) from $(0.20), and FY2028 to $(0.02) from positive $0.04. Estimates for Q1–Q4 2027 were also reduced, suggesting profitability may arrive later than previously expected.
• Negative Sentiment: The company’s latest quarterly loss of $(0.26) per share exceeded the expected $(0.21) loss, highlighting ongoing profitability pressure despite revenue exceeding expectations. SOPH remains deeply unprofitable, which could limit further gains if growth or the path to breakeven weakens.

SOPHiA GENETICS Price Performance

Shares of SOPHiA GENETICS stock opened at $7.71 on Monday. The business has a 50-day moving average price of $5.63 and a 200 day moving average price of $5.15. SOPHiA GENETICS SA has a fifty-two week low of $2.96 and a fifty-two week high of $7.86. The firm has a market cap of $646.79 million, a P/E ratio of -6.70 and a beta of 0.96. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The firm had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. On average, sell-side analysts forecast that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

SOPHiA GENETICS Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.